Letermovir Injection and Pivekimab Sunirine: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Letermovir Injection
Pivekimab Sunirine
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased pivekimab sunirine (GFN849) exposure and an increased risk of pivekimab sunirine-related adverse reactions
Interaction Deep Dive
Concomitant use of pivekimab sunirine with strong and moderate CYP3A inhibitors may increase unconjugated GFN849 exposure, which may increase the risk of pivekimab sunirine adverse reactions. Closely monitor patients for adverse reactions with pivekimab sunirine when used concomitantly with strong and moderate CYP3A inhibitors1.
Why it happens (mechanism)
Inhibition of CYP3A-mediated metabolism of pivekimab sunirine
Common questions
Can I take Letermovir Injection and Pivekimab Sunirine together?
Increased pivekimab sunirine (GFN849) exposure and an increased risk of pivekimab sunirine-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Letermovir Injection and Pivekimab Sunirine interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Letermovir Injection or Pivekimab Sunirine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: DECNUPAZ™ intravenous injection, pivekimab sunirine-pvzy intravenous injection. AbbVie Inc. North Chicago, IL, 2026. DailyMed
Keep reading about Letermovir Injection
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist